SOURCE: Peregrine Pharmaceuticals

Peregrine Pharmaceuticals

March 01, 2012 08:00 ET

Peregrine Announces Seven Abstracts Accepted for Presentation at AACR 2012 Annual Meeting

Data From Three Investigator Sponsored Bavituximab Clinical Trials to Be Presented

TUSTIN, CA--(Marketwire - Mar 1, 2012) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today announced that data from seven clinical and preclinical studies investigating the company's lead clinical candidates bavituximab and Cotara®, as well as other PS-targeting antibodies and fragments have been accepted for poster presentation at the 103rd Annual Meeting of the American Association for Cancer Research (AACR), to be held at McCormick Place in Chicago, Illinois, March 31 - April 4, 2012.

Abstracts Accepted at AACR:

Abstract Number: 1744
Presentation Title: A phase Ib study of bavituximab plus carboplatin and pemetrexed in chemotherapy naive stage IV non-squamous non-small cell lung cancer
Presentation Time: Monday, Apr 02, 2012, 8:00 AM - 12:00 PM
Location: McCormick Place West (Hall F), Poster Section 27
Poster Board Number: 4
Author Block: Juneko Grilley-Olson1, Jared Weiss1, Thomas E. Stinchcombe1, Anastasia Ivanova1, Maureen Tynan1, Joseph Shan2, Mark A. Socinski3. 1. Univ. of North Carolina, Chapel Hill, NC; 2. Peregrine Pharmaceuticals, Inc., Tustin, CA; 3. Univ. of Pittsburgh, Pittsburgh, PA

Abstract Number: 2510
Presentation Title: Increased Fc-FcR interaction of human phosphatidylserine targeting antibody enhances pro-inflammatory and ADCC anti-tumor mechanisms
Presentation Time: Monday, Apr 02, 2012, 1:00 PM - 5:00 PM
Location: McCormick Place West (Hall F), Poster Section 19
Poster Board Number: 5
Author Block: Jeanette R. Doerr1, Gary Larson1, Rich Archer1, Jian Gong1, Van Nguyen1, Aditi Iyengar1, Amy E. Johnson1, Mary Wakabayashi1, Matthew Peacock2, Christopher Hughes2, Connie Chang1, Bruce Freimark1. 1. Peregrine Pharmaceuticals, Tustin, CA; 2. Univ. of California at Irvine, Irvine, CA

Abstract Number: 2452
Presentation Title: Tumor detection and measurement of responses to chemotherapy using human phosphatidylserine targeting antibody fragments
Presentation Time: Monday, Apr 02, 2012, 1:00 PM - 5:00 PM
Location: McCormick Place West (Hall F), Poster Section 16
Poster Board Number: 25
Author Block: Jian Gong1, Rich Archer1, Matthew Peacock2, Christopher Hughes2, Connie Chang1, Bruce Freimark1. 1. Peregrine Pharmaceuticals, Inc., Tustin, CA; 2. Univ. of California at Irvine, Irvine, CA

Abstract Number: 2454
Presentation Title: In vivo binding of chTNT-1/B antibodies (Cotara) to DNA/histone complexes in tumors using near-infrared optical imaging
Presentation Time: Monday, Apr 02, 2012, 1:00 PM - 5:00 PM
Location: McCormick Place West (Hall F), Poster Section 16
Poster Board Number: 27
Author Block: Jian Gong1, Roy Sevilla1, Vince Nguyen1, Seth Fisher1, Jessica Alldredge1, Jessie Kinjo1, Rich Archer1, Matthew Peacock2, Christopher Hughes2, Connie Chang1, Bruce Freimark1. 1. Peregrine Pharmaceuticals, Inc., Tustin, CA; 2. Univ. of California at Irvine, Irvine, CA

Abstract Number: 4395
Presentation Title: Cure of castration-resistant prostate cancer in TRAMP mice by reactivating tumor immunity with a phosphatidylserine-targeting antibody
Presentation Time: Tuesday, Apr 03, 2012, 1:00 PM - 5:00 PM
Location: McCormick Place West (Hall F), Poster Section 19
Poster Board Number: 12
Author Block: Yi Yin, Xianming Huang, Gustavo Barbero, Dan Ye, Philip E. Thorpe. UT Southwestern Medical Ctr., Dallas, TX

Abstract Number: 4404
Presentation Title: Microparticle generation and activation after treatment with paclitaxel and bavituximab combination therapy in metastatic breast cancer
Presentation Time: Tuesday, Apr 03, 2012, 1:00 PM - 5:00 PM
Location: McCormick Place West (Hall F), Poster Section 19
Poster Board Number: 21
Author Block: Marilyn T. Marron, Pavani Chalasani, Daniel Camacho, Maria Iannone, Kathy Schmidt, Alison Stopeck. Univ. of Arizona, Tucson, AZ

Abstract Number: 5591
Presentation Title: A phase I study of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC)
Presentation Time: Wednesday, Apr 04, 2012, 8:00 AM - 12:00 PM
Location: McCormick Place West (Hall F), Poster Section 28
Poster Board Number: 9
Author Block: Adam Yopp, Yull Arriega, Amit Singal, John Mansour, Glen Balch, Phillip Thorpe. UT Southwestern Medical Center, Dallas, TX

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and infectious disease. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Contact Information

  • Contact:
    Chris Keenan or Jay Carlson
    Peregrine Pharmaceuticals, Inc.
    (800) 987-8256
    info@peregrineinc.com